Health care reforms envisaged in Hungary

18 December 2006

The Hungarian government is preparing a range of radical reforms of the health service focusing in particular on a comprehensive re-organization of the hospital sector, higher standards for general practitioners and charges for medical visits.

The current system has seen large increases in costs but without generating improved health. Hungarian life expectancy is around 72.4 years - fairly low in the Organization of Economic Cooperation and Development league table and well below neighboring Austria's 78.5 years, which was achieved with lower health service costs.

The Gyucsany regime in Budapest has now been pressurized into action by the health budget which is showing a deficit of over 10% of Gross Domestic Product. A range of patient charges appears inevitable, given that 1.3 million people currently receive medical services without paying a single forint.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight